Literature DB >> 10412842

Messenger molecules and receptor mRNA in the human trigeminal ganglion.

J Tajti1, R Uddman, S Möller, F Sundler, L Edvinsson.   

Abstract

The presence and distribution of neuromessenger molecules and receptor mRNA in human trigeminal ganglion was studied with immunocytochemical, in situ hybridisation and RT-PCR techniques. Immunofluorescence staining revealed that calcitonin gene-related peptide (CGRP) immunoreactive (-ir) neurons occurred in high numbers, constituting 36-40% of all nerve cell bodies in the ganglion. Accordingly, in situ hybridisation demonstrated CGRP mRNA in a large portion of the trigeminal neurons. A small number of the nerve cell bodies showed substance P (SP)-ir, (18%), nitric oxide synthase (NOS)-ir (15%), and pituitary adenylate cyclase activating peptide (PACAP)-ir (20%). Double immunostaining revealed that only few CGRP-ir neurons also were NOS-ir (less than 5%). The C-terminal flanking peptide of neuropeptide Y, C-PON, was not visible in any of the nerve cell bodies studied. Agarose gel electrophoresis of the RT-PCR products from the ganglia demonstrated the presence of mRNA corresponding to CGRP1, NPY Y1 and Y2, and VIP1 receptors. These results suggest both sympathetic and parasympathetic influence on the activity in the trigeminal ganglion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412842     DOI: 10.1016/s0165-1838(99)00024-7

Source DB:  PubMed          Journal:  J Auton Nerv Syst        ISSN: 0165-1838


  48 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery.

Authors:  L Edvinsson; E Nilsson; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 3.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 4.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 5.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 6.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

7.  Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons.

Authors:  Ilya Buldyrev; Nathan M Tanner; Hui-ya Hsieh; Emily G Dodd; Loi T Nguyen; Agnieszka Balkowiec
Journal:  J Neurochem       Date:  2006-10-25       Impact factor: 5.372

Review 8.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 9.  Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.

Authors:  L Edvinsson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 10.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.